Abiopharma

🔍 Tan Lee Su-Leng (Director)

Company: BioNexus Gene Lab Corp (BGLC)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 338,709 shares of Common Shares (Direct)
  Date: 2026-08-13 | Code: A | equity_swap_involved: 0 | shares_owned_after: 338,709.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Represents a fully vested Other Stock-Based Award of 338,709 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).